



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b>  <b>A61K 31/44, 9/08</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 94/02141</b>  <b>(43) International Publication Date:</b> 3 February 1994 (03.02.94)
<b>(21) International Application Number:</b> PCT/JP93/00998 <b>(22) International Filing Date:</b> 15 July 1993 (15.07.93)  <b>(30) Priority data:</b> 4/201203 28 July 1992 (28.07.92) JP  <b>(71) Applicants (for all designated States except US):</b> FUJISAWA PHARMACEUTICAL CO., LTD. [JP/JP]; 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541 (JP). YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. [JP/JP]; 6-9, Hiranomachi 2-chome, Chuo-ku, Osaka-shi, Osaka 541 (JP).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only) :</b> NAKANISHI, Shigeo [JP/JP]; 12-5, Shimokidacho, Neyagawa-shi, Osaka 572 (JP). TOMINAGA, Tetsuo [JP/JP]; B-806, Kasugaoka-Abankonfoto, 136-3, Kasugaoka 2-chome, Itami-shi, Hyogo 664 (JP). YAMANATA, Iwao [JP/JP]; 5-6-12, Kamiminami, Hirano-ku, Osaka-shi, Osaka 547 (JP). HIGO, Takashi [JP/JP]; 2-2-10, Midorigaoka, Ikeda-shi, Osaka 563 (JP). SHIBATA, Toshiyuki [JP/JP]; 774-105, Oaza-Higashihama, Nakatsu-shi, Oita 871 (JP).		<b>(74) Agent:</b> TAKASHIMA, Hajime; Yuki Building, 3-9, Hiranomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541 (JP).  <b>(81) Designated States:</b> AU, BB, BG, BR, BY, CA, CZ, FI, HU, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> INJECTION AND INJECTION KIT CONTAINING OMEPRAZOLE AND ITS ANALOGS  <b>(57) Abstract</b>  <p>An injection comprising a 2-[(2-pyridyl)methylsulfinyl]-benzimidazole compound or a salt thereof having antiulcer activity and an aqueous solvent added with no nonaqueous solvent, wherein the pH of the injection is not less than 9.5 and not more than 11.5, and an injection kit comprising the following (a) and (b), wherein (a) and (b) are adjusted such that the pH upon dissolution of (a) in (b) is 9.5 - 11.5: (a): a lyophilized product of an alkaline aqueous solution of a 2-[(2-pyridyl)methylsulfinyl]benzimidazole compound or salt thereof having antiulcer activity; (b): an aqueous solvent added with no nonaqueous solvent. The injection of the present invention is void of the necessity to lower pH so as to prevent hemolysis and local irritation, and to add a nonaqueous solvent to an aqueous solvent for dissolution so as to prevent concomitant degradation of dissolution property. Accordingly, the injection of the present invention can secure solubility sufficient for formulation into preparation and safety for the human body.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
RJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

## SPECIFICATION

## INJECTION AND INJECTION KIT CONTAINING OMEPRAZOLE AND ITS ANALOGS

## [TECHNICAL FIELD]

The present invention relates to an injection of 2-[(2-pyridyl)methylsulfinyl]benzimidazole compound or a salt thereof having antiulcer activity, particularly sodium salt of omeprazole and to an injection kit thereof, which are used in clinical fields.

## [BACKGROUND ART]

The 2-[(2-pyridyl)methylsulfinyl]benzimidazole compounds such as omeprazole or lansoprazole are potent antiulcer agents, and are used as pharmaceutical compositions for oral administration. Further, the injections thereof have recently developed.

As an injection of omeprazole, there has been known an injection prepared by dissolving sodium salt of omeprazole in sterilized water, filtering and lyophilizing the solution to give a lyophilized product, and then dissolving the lyophilized product in a mixture of polyethylene glycol 400 for injection, sodium dihydrogenphosphate and sterilized water (Japanese Patent Unexamined Publication No. 167587/1984).

Also, an injection prepared by dissolving a lyophilized product of an alkaline aqueous solution of a 2-[(2-pyridyl)-methylsulfinyl]benzimidazole compound having antiulcer activity such as lansoprazole in a mixture of (a) acid, and (b) at least one of ethanol, propylene glycol and polyethylene glycol

(Japanese Patent Unexamined Publication No. 138213/1990).

In general, the pH of injection is preferably about 4-8, and a pH above 9 has a probability of causing hemolysis and local irritation.

In the case of the 2-[(2-pyridyl)methylsulfinyl]benzimidazole compound or a salt which may be hereinafter referred to as "benzimidazole compound or salt thereof" represented by sodium salt of omeprazole, it shows a solubility of the level permitting formulation into preparation, in water in an alkaline range of pH 9.5 or above, whereas it shows extremely low solubility in water at a pH of not more than 9, thus rendering formulation into preparation very difficult.

While the benzimidazole compound or salt thereof is stable in the alkaline range, it poses a problem in that its stability decreases with the lowering pHs.

For this reason, it has been employed in conventional injections of benzimidazole compound or salt thereof such as sodium salt of omeprazole to add an acid such as hydrochloric acid or sodium dihydrogenphosphate to the solution to keep the pH from neutral to weak basic, and to further add a nonaqueous solvent such as polyethylene glycol, ethanol or propylene glycol in order to obtain a certain level of solubility in such pH range.

Yet, these injections pose problems of local irritation and hemolysis caused by the nonaqueous solvent added to the solution for dissolution.

Accordingly, an object of the invention is to provide an injection of benzimidazole compound or salt thereof, particularly sodium salt of omeprazole causing less side-effects such as hemolysis, and less local irritation, which permits easy formulation.

#### [DISCLOSURE OF THE INVENTION]

As a result of the intensive study conducted by the inventors with the aim of achieving the aforementioned object, it has now been found that a product obtained by lyophilizing an alkaline aqueous solution of benzimidazole compound or salt thereof, and dissolving same in an aqueous solvent added with no nonaqueous solvent scarcely shows hemolytic property and local irritation, notwithstanding the high pH of from 9.5 to 11.5.

Accordingly, the present invention is:

- (1) an injection comprising a 2-[(2-pyridyl)methylsulfinyl]-benzimidazole compound or a salt thereof having antiulcer activity and an aqueous solvent added with no nonaqueous solvent, which has a pH of not less than 9.5 and not more than 11.5,
- (2) an injection kit comprising the following (a) and (b), wherein (a) and (b) are adjusted such that the pH upon dissolution of (a) in (b) is not less than 9.5 and not more than 11.5;
  - (a) : a lyophilized product of an alkaline aqueous solution of a 2-[(2-pyridyl)methylsulfinyl]benzimidazole compound or a salt

thereof having antiulcer activity

(b) : an aqueous solvent added with no nonaqueous solvent.

The 2-[(2-pyridyl)methylsulfinyl]benzimidazole compounds having antiulcer activity which are the element constituting the present invention include, for example, the compounds described in Japanese Patent Unexamined Publication No. 62275/1977, Japanese Patent Unexamined Publication No. 1417/1979, Japanese Patent Unexamined Publication No. 53406/1982, Japanese Patent Unexamined Publication No. 135881/1983, Japanese Patent Unexamined Publication No. 192880/1983, Japanese Patent Unexamined Publication No. 181277/1984 or Japanese Patent Unexamined Publication No. 50978/1986, and omeprazole [chemical name: 2-[2-(3,5-dimethyl-4-methoxy)-pyridylmethylsulfinyl]-(5-methoxy)benzimidazole] and lansoprazole [chemical name: 2-{2-[(3-methyl-4-(2,2,2-trifluoroethoxy)]-pyridylmethylsulfinyl} - benzimidazole] are exemplified.

As the salts of said benzimidazole compounds, for example, salts of alkaline metal such as sodium salt or potassium salt or salts of alkaline earth metal such as calcium salt or magnesium salt.

In view of the solubility, it is preferable for the present invention to use the salt of benzimidazole compound.

The injection of the present invention has a pH of not less than 9.5 and not more than 11.5, preferably not less than 10 and not more than 11. Where the pH is less than 9.5, the benzimidazole compound or salt thereof does not sufficiently

dissolve in an aqueous solvent and shows poor stability, while where it is more than 11.5, hemolytic property and local irritation become prominent.

According to the present invention, an injection of the benzimidazole compound or salt thereof can be prepared by dissolving the benzimidazole compound or salt thereof in water for injection, etc. along with a strong alkaline compound such as sodium hydroxide, potassium hydroxide, sodium carbonate or L-arginine, to give an alkaline aqueous solution having a pH adjusted to not less than 10.5 and not more than 12.5, preferably not less than 11 and not more than 12. The alkaline aqueous solution may contain mannitol, glycine, sorbitol, inositol, etc. on demand for better forming of a lyophilized product.

The benzimidazole compound is contained in said alkaline aqueous solution in a proportion of 1-50 mg/ml, preferably 5-40 mg/ml on a free compound basis.

Then, this alkaline aqueous solution is filtered for sterilization, and charged in a vial by 0.5-10 ml. After nitrogen gas displacement to be conducted as necessary, the solution is lyophilized by a method known per se. The lyophilized product thus obtained is the (a): a lyophilized product of an alkaline aqueous solution of the 2-[(2-pyridyl)-methylsulfinyl]benzimidazole compounds or salt thereof having antiulcer activity to be contained in the injection kit of the present invention.

When in use, the injection of the present invention can be produced by dissolving the lyophilized product thus obtained in an aqueous solvent added with no nonaqueous solvent, such as physiological saline, aqueous solution of 5% glucose, or distilled water for injection. Said aqueous solvent corresponds to the (b) : an aqueous solvent added with no nonaqueous solvent to be contained in the injection kit of the present invention.

The injection of the present invention can be used, for example, in the form of drip infusion, intravenous injection, intramuscular injection, subcutaneous injection.

The concentration of benzimidazole compound in the injection of the present invention may vary depending upon the administration route, and generally ranges in a proportion of 0.05-10 mg/ml, preferably 0.1-5 mg/ml on a free compound basis.

The benzimidazole compound in the injection of the present invention is administered to an adult at 10-100 mg per day on a free compound basis in a single to three times divided doses, depending upon, for example, the symptoms of the patients.

#### [BEST MODE FOR CARRYING OUT OF THE INVENTION]

##### Experimental Example 1

##### Test preparation

1. Preparation obtained in Example 1 to be mentioned later

##### Test method

1. Hemolysis test

Hemolysis was evaluated by Akaishi method using whole blood



of rabbit. The result is given in Table 1.

## 2. Local irritation test

Local irritation was evaluated by the comparison of necrotic muscular tissue area at the injection site in 3 rabbits at 2 days after the administration of 1 ml of the test preparation by intramuscular injection, with that in the rabbits administered with 1 ml of physiological saline or 1 ml of a 1.7% acetic acid solution, respectively by intramuscular injection.

The results are summarized in Table 2.

### Test results

Table 1

Test preparation	pH	Hemolysis
Ex. 1	10.5	not observed

Table 2

Test preparation	pH	Necrotic area (mm <sup>2</sup> )
Ex. 1	10.5	63
1.7% acetic acid solution (positive comparison solution)	—	398
physiological saline (negative comparison solution)	—	31

(average of 3 rabbits)

The preparation of the present invention is desirable as an injection, since it does not cause hemolysis at all despite the high pH, and causes less local irritation.

#### Example 1

1N Sodium hydroxide (2.3 ml) is added to 21.3 g of sodium salt of omeprazole (20 g as omeprazole), and water for injection is added thereto to adjust the pH to 11.5 and the total amount to 1 kg.

After filtration for sterilization, this alkaline aqueous solution is charged in 10 ml vials by 2 g. A rubber plug is half driven in, and nitrogen displacement is performed. Lyophilization by a conventional method and dissolution of the lyophilized product obtained in 10 ml of physiological saline give an omeprazole injection [4 mg (free compound)/ml].

#### [INDUSTRIAL APPLICABILITY]

The injection of the present invention is void of the necessity to lower pH so as to prevent hemolysis and local irritation, and to add a nonaqueous solvent such as polyethylene glycol to an aqueous solvent for dissolution so as to prevent concomitant degradation of dissolution property. As a result, irritation and hemolysis caused by the nonaqueous solvent can be avoided. Accordingly, the injection of the present invention can secure solubility sufficient for formulation into preparation and safety for the human body.

## CLAIMS

1. An injection comprising a 2-[(2-pyridyl)methylsulfinyl]-benzimidazole compound or a salt thereof having antiulcer activity and an aqueous solvent added with no nonaqueous solvent, wherein the pH of the injection is not less than 9.5 and not more than 11.5.
2. The injection of Claim 1, prepared by dissolving a lyophilized product of an alkaline aqueous solution of the 2-[(2-pyridyl)methylsulfinyl]benzimidazole compound or a salt thereof having antiulcer activity in the aqueous solvent added with no nonaqueous solvent.
3. An injection kit comprising the following (a) and (b), wherein (a) and (b) are adjusted such that the pH upon dissolution of (a) in (b) is not less than 9.5 and not more than 11.5;  
(a) : a lyophilized product of an alkaline aqueous solution of a 2-[(2-pyridyl)methylsulfinyl]benzimidazole compound or a salt thereof having antiulcer activity  
(b) : an aqueous solvent added with no nonaqueous solvent.
4. The injection of Claim 1 or 2, wherein the 2-[(2-pyridyl)methylsulfinyl]benzimidazole compound or a salt thereof is sodium salt of omeprazole.
5. The injection kit of Claim 3, wherein the 2-[(2-pyridyl)methylsulfinyl]benzimidazole compound or the salt thereof is sodium salt of omeprazole.

## INTERNATIONAL SEARCH REPORT

PCT/JP 93/00998

International Application No

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl. 5 A61K31/44; A61K9/08		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
Int.Cl. 5	A61K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b>		
Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
A	EP,A,0 382 489 (TAKEDA) 16 August 1990 see claims see page 7, line 50 - line 52 see example 2 ---	1-5
A	EP,A,0 124 495 (AKTIEBOLAGET HÄSSLE) 7 November 1984 cited in the application see claims see page 6, line 6 - line 15 see page 7, line 31 - line 37 see page 8, line 1 - line 8 see example 13 ---	1-5
A	EP,A,0 356 143 (TAKEDA) 28 February 1990 cited in the application see claims -----	1-5
<sup>10</sup> Special categories of cited documents : <sup>"A"</sup> document defining the general state of the art which is not considered to be of particular relevance <sup>"E"</sup> earlier document but published on or after the international filing date <sup>"L"</sup> document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) <sup>"O"</sup> document referring to an oral disclosure, use, exhibition or other means <sup>"P"</sup> document published prior to the international filing date but later than the priority date claimed <sup>"T"</sup> later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention <sup>"X"</sup> document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step <sup>"Y"</sup> document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. <sup>"A"</sup> document member of the same patent family		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search 29 SEPTEMBER 1993		Date of Mailing of this International Search Report 07.10.93
International Searching Authority EUROPEAN PATENT OFFICE		Signature of Authorized Officer SCARPONI U.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.**

JP 9300998  
SA 76470

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 29/09/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0382489	16-08-90	CA-A- 2009741	10-08-90
		JP-A- 3173817	29-07-91
		US-A- 5013743	07-05-91
EP-A-0124495	07-11-84	AU-B- 563842	23-07-87
		AU-A- 2525784	06-09-84
		CA-A- 1264751	23-01-90
		GB-A, B 2137616	10-10-84
		JP-C- 1651336	30-03-92
		JP-B- 3013233	22-02-91
		JP-A- 59167587	21-09-84
		SU-A- 1314953	30-05-87
		US-A- 4738974	19-04-88
EP-A-0356143	28-02-90	JP-A- 2138213	28-05-90
		US-A- 5223515	29-06-93